On the 27th, Paxlovid, an oral treatment for COVID-19, was approved for EUA by the MFDS, and the Pharmaceutical Association for Health Society asked questions about the insolvency and effectiveness of the screening process on the 30th.

The Health Pharmaceutical Association said, "Paxlovid is expected to be used in patients with high risk among mild and moderate coronavirus patients, and is known to have side effects such as taste abnormalities, diarrhea, and elevated blood pressure, and to be careful of various drugs such as anti-antibodymetic drugs." The Pharmaceutical Association said it would inquire about ▲ the inadequacy of the Ministry of Food and Drug Safety's examination process, ▲ possibility o